Connect Biopharma reports Q1 net loss $19.4M; Phase 2 studies on track, topline data mid-2026

Connect Biopharma Holdings Ltd

2026-Q1 EPS reported -$0.34 revenue$169,000

Net loss $19.4M ($0.34 loss per share) vs $10.3M loss ($0.19 per share) in Q1 2025.
Cash $46.0M as of March 31, 2026; expects funding into H2 2027.
Phase 2 Seabreeze STAT asthma/COPD studies continuing after DMC review; topline data expected mid-2026.
Completed $20.2M private placement led by Panacea Venture on March 31, 2026.
R&D expense $15.0M (up from $6.6M) due to rademikibart development; license revenue $0.2M from Simcere agreement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Connect Biopharma Holdings Ltd reported the three months ended March 31, 2026 results: revenue $0.2 million, net income $19.4 million, EPS ($0.34) per share.

Period: the three months ended March 31, 2026
Revenue: $0.2 million
Net income: $19.4 million
EPS: ($0.34) per share
Result: reported results

Exact text from the filing

its cash and investments will be sufficient to fund operations into the second half of 2027. • License and collaboration revenues for the three months ended March 31, 2026 were $0.2 million related to the upfront license fee under the license agreement with Simcere. There were no license and collaboration revenues for the three months ended March 31, 2025. As a part

View on SEC.gov

554 earnings releases filed in the last 30 days. Browse all earnings releases →

Connect Biopharma Holdings Ltd filing history →

Source: SEC EDGAR

accession 0001835268-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.